Creative Biotherapeutics, LLC announced continued progress in the preclinical development of CBT300, an investigational biologic therapeutic candidate. The program focuses on mechanisms associated with drug resistance, immune evasion, recurrence, and metastasis, with the goal of advancing toward FDA-regulated clinical trials through an evidence-based development pathway. The company is led by clinician Anita Davidson and biochemist Dr. Don Davidson, who bring decades of patient care and drug development experience to the effort.
For Anita Davidson, the work is rooted in clinical reality, having recently lost a sixteen-year-old patient to a form of brain cancer that returned rapidly despite treatment. "There are losses that stay with you," Davidson said. "You remember the families, the hopes, and the urgency. That child is a reason I keep working." This personal motivation underscores the company's mission to address the challenges that lead to treatment failure. Dr. Don Davidson emphasized that cancer outcomes are often shaped by recurrence and resistance, stating, "Our development work focuses on mechanisms associated with relapse and treatment escape so future therapies can be evaluated with that reality in mind."
CBT300 is being developed as a multi-mechanism biologic candidate intended to interfere with drug-resistance pathways, immune-evasion mechanisms, and cellular processes associated with recurrence and metastasis. The company reports issued and pending patents related to its platform and lead program, with research and validation ongoing. Development decisions are guided by a disciplined, evidence-based approach as it progresses through regulatory preparation. Davidson also highlighted tolerability as an important consideration, noting, "Patients and families live with the full burden of treatment. We want development pathways that respect patients and are guided by real-world experience."
Creative Biotherapeutics is preparing remaining components required to support advancement toward clinical trials, including continued research, validation, and regulatory readiness. Dr. Davidson stated, "We are working diligently toward entering clinical trials. Progress has to be earned through data, discipline, and integrity." The company is sharing information publicly to support awareness among patients, clinicians, and the scientific community regarding CBT300 and its development progress. For more information, visit the official website.
The company welcomes mission-aligned collaboration inquiries related to the responsible development of CBT300 and the advancement of science-driven oncology solutions, including research collaborations, clinical and scientific partnerships, and development and regulatory alignment opportunities. Collaboration inquiries can be directed here with a brief description of organizational role and interest area. This news matters because it represents a targeted approach to overcoming some of the most persistent barriers in cancer treatment, potentially offering new hope for patients facing aggressive cancers where current therapies fall short due to resistance or recurrence.
